These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31700636)

  • 1. Single-centre experience with anti-tumour necrosis factor treatment in budesonide-refractory microscopic colitis patients.
    Daferera N; Hjortswang H; Ignatova S; Münch A
    United European Gastroenterol J; 2019 Nov; 7(9):1234-1240. PubMed ID: 31700636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis: a Multicentre Cohort Study from the GETAID.
    Boivineau G; Zallot C; Zerbib F; Plastaras L; Amiot A; Boivineau L; Koch S; Peyrin-Biroulet L; Vuitton L
    J Crohns Colitis; 2022 Dec; 16(12):1816-1824. PubMed ID: 35793161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
    Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
    United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Vedolizumab and Tumor Necrosis Factor Inhibitors in the Treatment of Steroid-refractory Microscopic Colitis: A Systematic Review and Meta-analysis.
    El Hage Chehade N; Ghoneim S; Shah S; Pardi DS; Farraye FA; Francis FF; Hashash JG
    J Clin Gastroenterol; 2024 Sep; 58(8):789-799. PubMed ID: 37668427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
    Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
    Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with long-term clinical outcome in microscopic colitis.
    Miyatani Y; Komaki Y; Komaki F; Micic D; Keyashian K; Sakuraba A
    Ann Med; 2024 Dec; 56(1):2365989. PubMed ID: 38900021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of budesonide in the treatment of microscopic colitis.
    Tangri V; Chande N
    Saudi J Gastroenterol; 2010; 16(3):236-8. PubMed ID: 20616427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.
    Münch A; Mihaly E; Nagy F; Madisch A; Kupčinskas J; Miehlke S; Bohr J; Bouma G; Guardiola J; Belloc B; Shi C; Aust D; Mohrbacher R; Greinwald R; Munck LK
    United European Gastroenterol J; 2021 Sep; 9(7):837-847. PubMed ID: 34414678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group.
    Fernández-Bañares F; Casanova MJ; Arguedas Y; Beltrán B; Busquets D; Fernández JM; Fernández-Salazar L; García-Planella E; Guagnozzi D; Lucendo AJ; Manceñido N; Marín-Jiménez I; Montoro M; Piqueras M; Robles V; Ruiz-Cerulla A; Gisbert JP;
    Aliment Pharmacol Ther; 2016 Feb; 43(3):400-26. PubMed ID: 26597122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microscopic colitis: clinical characteristics, treatment and outcomes in an Irish population.
    O'Toole A; Coss A; Holleran G; Keegan D; Doherty G; Sheahan K; Mulcahy H; O'Donoghue D
    Int J Colorectal Dis; 2014 Jul; 29(7):799-803. PubMed ID: 24743846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab in Refractory Microscopic Colitis: An International Case Series.
    Rivière P; Münch A; Michetti P; Chande N; de Hertogh G; Schoeters P; Ferrante M; Vermeire S; Van Assche G
    J Crohns Colitis; 2019 Mar; 13(3):337-340. PubMed ID: 30329034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR; Steenholdt C; Brynskov J
    Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anti-TNF therapies in refractory severe microscopic colitis.
    Esteve M; Mahadevan U; Sainz E; Rodriguez E; Salas A; Fernández-Bañares F
    J Crohns Colitis; 2011 Dec; 5(6):612-8. PubMed ID: 22115383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beclomethasone dipropionate in microscopic colitis: Results of an exploratory open-label multicentre study (COLCO).
    Corte T; Janssens E; D'Hondt A; Thorrez K; Arts J; Dejaegher K; D'Heygere F; Holvoet A; van Besien B; Harlet L; Peeters H; Moerkercke WV; Baert F
    United European Gastroenterol J; 2019 Nov; 7(9):1183-1188. PubMed ID: 31700631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial.
    Bonderup OK; Hansen JB; Teglbjaerg PS; Christensen LA; Fallingborg JF
    Gut; 2009 Jan; 58(1):68-72. PubMed ID: 18669576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
    Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
    Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.